How does mycophenolate mofetil prevent my transplanted organ from being rejected?
Mycophenolate mofetil blocks the growth of T and B lymphocytes—the white blood cells that attack foreign organs—by cutting off their guanosine supply. This selective brake reduces acute rejection risk by 30–40% in kidney, heart, and liver transplant recipients [1].
The FDA landmark trial showed that kidney transplant patients on mycophenolate mofetil 1,000 mg twice daily had acute rejection rates of 19% versus 43% on placebo over one year [1]. The drug works by inhibiting an enzyme called IMPDH, which T and B cells need to multiply. Other body cells can bypass this block using a salvage pathway, so mycophenolate mofetil spares your gut, bone marrow, and heart while silencing the immune attack on your new organ [9].
Think of your immune system as a security guard. Normally, it spots the transplanted kidney as a trespasser and calls in reinforcements—T cells and B cells multiply like a swarm. Mycophenolate mofetil whispers to those cells: 'Stop multiplying.' Without enough guanosine nucleotides, they can't divide, and the rejection alarm never sounds [1].
In real life, mycophenolate mofetil is almost never used alone. Your transplant team pairs it with a calcineurin inhibitor (tacrolimus or cyclosporine) and low-dose prednisone to hit rejection from three angles [1]. If you skip doses or halve your dose without permission, rejection risk jumps 15–20% within weeks. Always call your surgeon before changing anything [9].
Ask your transplant coordinator: 'What's my target mycophenolic acid (MPA) level, and how often will you check it?' Levels of 30–60 μg·h/mL predict the best balance between rejection prevention and side effects. Some centers use therapeutic drug monitoring (TDM) to personalize your dose [1].